FDA issues Flonase, Nasonex letters

Share this article:
The FDA's Division of Drug Marketing, Advertising and Communications has issued untitled letters of violation to Schering-Plough for its Nasonex nasal spray, and to GlaxoSmithKline for its Flonase nasal spray, concerning detail aids used by reps for both brands.

The agency said the sales aids were false and misleading in making superiority claims over each other.

GSK stopped detailing for Flonase in 2006 when the drug went generic. The company is expected to take into account the FDA guidance to develop promotional material for its Flonase follow-on Veramyst.

Schering-Plough spokeswoman Mary-Fran Faraji told The Wall Street Journal the company had already replaced the Nasonex promotional materials. After receiving the FDA letter, the company told its sales reps not to use the old selling aids anymore. The company responded to FDA in writing and is working with the agency to resolve its concerns, she said.  

Share this article:

Email Newsletters

More in News

Star Group merges with Vox Medica, Calcium NYC

Star Group merges with Vox Medica, Calcium NYC

The newly formed group will be known as Calcium with Steve Michaelson, formerly of Rosetta Wishbone, at the helm.

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...